{"id":38279,"date":"2025-07-31T12:58:14","date_gmt":"2025-07-31T04:58:14","guid":{"rendered":"https:\/\/flcube.com\/?p=38279"},"modified":"2025-07-31T12:58:15","modified_gmt":"2025-07-31T04:58:15","slug":"walvax-expands-rights-to-notitias-gut-microbiota-therapy-in-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38279","title":{"rendered":"Walvax Expands Rights to Notitia\u2019s Gut Microbiota Therapy in Greater China"},"content":{"rendered":"\n

Walvax Biotechnology Co., Ltd (SHE: 300142<\/a>), a Chinese biopharmaceutical company, has announced that an amendment to its Exclusive Sublicense Agreement with US-based Notitia Biotechnologies, a microbiome-targeted biotherapeutic company. Through this amendment, Walvax secures exclusive rights to develop, manufacture, and commercialize Notitia\u2019s proprietary gut microbiota therapy in mainland China, Hong Kong, and Macau, expanding beyond disease-specific populations to include non-patients focused on chronic disease prevention and health nutrition.<\/p>\n\n\n\n

Amended Agreement Details<\/strong>
Originally signed in May 2025, the initial agreement granted Walvax rights for disease-specific populations. The amendment enables a dual-track strategy: \u201cdisease treatment intervention\u201d and \u201cchronic disease prevention and control + health nutrition.\u201d This expansion highlights Walvax\u2019s commitment to leveraging Notitia\u2019s technology, licensed from Rutgers University, which integrates core microbiota analysis, targeted microbiota transplantation, and nutritional formulation.<\/p>\n\n\n\n

Financial Terms<\/strong>
Under the amendment, Walvax agreed to pay Notitia a licensing fee of USD 1.5 million. Additionally, Walvax is required to pay a continuous royalty of 6.5% of the net sales of the sublicense products, or according to the set minimum royalty. Upon achieving specific milestone events, Walvax will also make milestone payments of up to USD 39 million.-Fineline Info & Tech<\/a><\/p>\n\n\n\n